Authors
Latest:
The Role of Commercial Partners in Sales Strategy DevelopmentGreg Flynn discusses the advantages, challenges and possible future of CCOs and outlines their role in effective sales strategy development.
Latest:
Bridging the Diversity GapDiversity and inclusion shouldn’t be something that companies have to work hard at, writes Chris Coe.
Latest:
Adopting New Technology: Barriers and BreakthroughsPreserving positive ROI amid healthcare’s innovation explosion.
Latest:
Use of High-Efficacy Therapies in MSOpinion remains divided regarding how aggressively MS should be treated. Some neurologists believe in the “treat early, treat aggressively” approach, whilst others prefer to “save” HE therapies until the more traditional platform therapies have failed.
Latest:
IP Analysis Provides Insight to Formulate an Effective Business StrategyCreating an IP portfolio strategy that includes R&D, in-licensing, out-licensing, and mergers and acquisitions can help businesses stay ahead of the competition.
Latest:
Supporting Real-World Data Acquisition Using a Human-Centered Design Strategy Within Specialty PharmacySpecialty pharmacy's role in shifting the existing paradigm from a transactional model to an experiential model in ways that can fuel real-world data acquisition and strategy.
Latest:
Supporting Real-World Data Acquisition Using a Human-Centered Design Strategy Within Specialty PharmacySpecialty pharmacy's role in shifting the existing paradigm from a transactional model to an experiential model in ways that can fuel real-world data acquisition and strategy.
Latest:
Supporting Real-World Data Acquisition Using a Human-Centered Design Strategy Within Specialty PharmacySpecialty pharmacy's role in shifting the existing paradigm from a transactional model to an experiential model in ways that can fuel real-world data acquisition and strategy.
Latest:
Proposed Rebates Rule Raises Tough QuestionsThe decision to eradicate pharma rebates and prompt direct discounts for federal beneficiaries could, if passed, upend the market-what are the critical questions for new products?
Latest:
Clearing Up ‘Clear Evidence’ and Implications for Labeling Post-Merck DecisionIntellectual property attorneys discuss the clarified requirements for when state failure-to-warn claims are pre-empted by FDA regulations after the Supreme Court Merck case.
Latest:
Clearing Up ‘Clear Evidence’ and Implications for Labeling Post-Merck DecisionIntellectual property attorneys discuss the clarified requirements for when state failure-to-warn claims are pre-empted by FDA regulations after the Supreme Court Merck case.
Latest:
Changing Drug Benefit Design & Transparency to Impact Drug PricesRick Kelly and Nisha Desai provide an overview of the “American Patients First” blueprint's four key strategies.
Latest:
Making the Most of Maturing Oncology BrandsA checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.
Latest:
Making the Most of Maturing Oncology BrandsA checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.
Latest:
Making the Most of Maturing Oncology BrandsA checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.
Latest:
Making the Most of Maturing Oncology BrandsA checklist of best practices for mid-life products a few years after launch to help companies with growing oncology portfolios determine not only to see if there’s hidden vitality still left in their aging brands.
Latest:
NASH: Still WaitingSabina Heinz and Elizabeth Baynton look at how the continued absence of approved products affecting the management of NASH patients.
Latest:
Drug Formulary Decisions: Fixing a Broken SystemWhy the time is right for P&T committees to incorporate real-world data and ‘real-world science’ into their product assessments.
Latest:
The Argument for External Comparator AdoptionIts use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making.
Latest:
'Vision’ Quest: Leading Through ChangeExploring the critical go-to strategies for biopharma C-suite executives in navigating organizational disruption and the impact of global change and volatility on their employees and business.
Latest:
Transforming PV in Smaller Companies with Standardization and AutomationSmall- and medium-sized pharmas should revisit their pharmacovigilance strategies and adopt smarter end-to-end solutions to keep pace with increased volumes and rapidly changing regulatory requirements, writes Siva Thiagarajan.
Latest:
Clinical Evidence Key to Commercializing Life Science ProductsCompanies need to find compelling ways to present facts, rather than slick but insubstantial promotions.
Latest:
The Feasibility of Patient Insights Before LaunchObtaining patient perspectives during open-label extension trials.
Latest:
The Feasibility of Patient Insights Before LaunchObtaining patient perspectives during open-label extension trials.
Latest:
Patient-Centric Trials in China: An Opportunity to InnovateThe opportunities and challenges surrounding patient centricity and patient-centric trials in China.
Latest:
Patient-Centric Trials in China: An Opportunity to InnovateThe opportunities and challenges surrounding patient centricity and patient-centric trials in China.
Latest:
Patient-Centric Trials in China: An Opportunity to InnovateThe opportunities and challenges surrounding patient centricity and patient-centric trials in China.
Latest:
Patient-Centric Trials in China: An Opportunity to InnovateThe opportunities and challenges surrounding patient centricity and patient-centric trials in China.
